Skip To Main Content
P. Peter Ghoroghchian on Muck Rack

P. Peter Ghoroghchian

As seen in: Nature, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to P. Peter Ghoroghchian’s profile

Articles by P. Peter Ghoroghchian

Computational modeling and preclinical evaluation support targeting somatic instability for Huntington’s disease treatment

|
By Bryan Simpson, Paul T. Ranum, David E. Leib, Luis Tecedor, Ryan Giovenco, Icnelia Huerta-Ocampo, Noah Smith, Christopher P. Cali, Jamie Benoit, John Connelly, George Yohrling, P. Peter Ghoroghchian, Beverly L. Davidson, Amiel A. Hundley, Christopher M. Fluta, Jenna C. Soper, Jang-Ho J. Cha
| Nature Verified
Abstract Genetic modifiers of Huntington’s disease (HD) disease onset and progression implicate somatic instability (SI) of the expanded CAG repeat as a key pathogenic driver, with MSH3 emerging as a therapeutic target.
Open in Who Shared Issue with article?

Advancements in Nanomedicine for Multiple Myeloma

|
By Alexandre Detappe, Mark W. Bustoros, Tarek H. Mouhieddine, P. Peter Ghoroghchian
| Cell Press Verified
Palumbo A. Anderson K. Multiple myeloma. N. Engl. J. Med. 2011; 364: 1046-1060 Attal M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 2017; 376: 1311-1320 Stewart A.K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2015; 372: 142-152 Lonial S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 2015; 373: 621-631 Lokhorst H.M. et al.
Open in Who Shared Issue with article?
Show More